ArticleJournal of nanobiotechnology2014
PapMV nanoparticles improve mucosal immune responses to the trivalent inactivated flu vaccine.
Article in Journal of nanobiotechnology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Nanoparticles in influenza research: a bibliometric analysis of global trends (2005 - 2025).Frontiers in immunology · 2026Pooled it
- Nanomedicine for the Treatment of Viral Diseases: Smaller Solution to Bigger Problems.Pharmaceutics · 2024Review
- Influenza vaccine: a review on current scenario and future prospects.Journal, genetic engineering & biotechnology · 2023Review
- Review
- An Overview of Influenza Viruses and Vaccines.Vaccines · 2021Review
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- Plant virus particles with various shapes as potential adjuvants.Scientific reports · 2020Article
- Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform.Vaccines · 2019Article
- Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses.Frontiers in plant science · 2019Review
- A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.Journal of nanobiotechnology · 2017Article
- Efficacy of a Virus-Like Nanoparticle As Treatment for a Chronic Viral Infection Is Hindered by IRAK1 Regulation and Antibody Interference.Frontiers in immunology · 2017Article
- Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine.Journal of nanobiotechnology · 2016Article
- Induction of mucosal immunity through systemic immunization: Phantom or reality?Human vaccines & immunotherapeutics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTrivalent inactivated flu vaccines (TIV) are currently the best means to prevent influenza infections. However, the protection provided by TIV is partial (about 50%) and it is needed to improve the efficacy of protection. Since the respiratory tract is the main site of influenza replications, a vaccine that triggers mucosal immunity in this region can potentially improve protection against this disease. Recently, PapMV nanoparticles used as an adjuvant in a formulation with TIV administered by the subcutaneous route have shown improving the immune response directed to the TIV and protection against an influenza challenge.
findingsIn the present study, we showed that intranasal instillation with a formulation containing TIV and PapMV nanoparticles significantly increase the amount of IgG, IgG2a and IgA in lungs of vaccinated mice as compared to mice that received TIV only. Instillation with the adjuvanted formulation leads to a more robust protection against an influenza infection with a strain that is lethal to mice vaccinated with the TIV.
conclusionsWe demonstrate for the first time that PapMV nanoparticles are an effective and potent mucosal adjuvant for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.